PBA
MDGL icon

Paradigm Biocapital Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Paradigm Biocapital Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-85,000
Closed -$19.6M – 33
2023
Q2 		$19.6M Buy
+85,000
New +$23M 1.52% 26

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Paradigm Biocapital Advisors's MDGL Position: Q3 2023 in Review

Paradigm Biocapital Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2023, closing a stake of 85,000 shares — an estimated $19.6M sold.

Paradigm Biocapital Advisors first reported a position in MDGL in Q2 2023 and held it in 1 quarter. The position peaked at $19.6M in Q2 2023. 205 funds tracked by Wall St. Rank hold MDGL as of Q3 2023.

  • Paradigm Biocapital Advisors reported no remaining Madrigal Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 85,000 Madrigal Pharmaceuticals shares in Q3 2023, an estimated $19.6M.
  • Paradigm Biocapital Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Paradigm Biocapital Advisors's Madrigal Pharmaceuticals position peaked at $19.6M in Q2 2023.
  • 205 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2023.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.